Epigenetic Technology Market Worth $8 Billion by 2017 - Report by Marketsandmarkets

Epigenetics is one of the fastest emerging scientific fields with promising growth potential to revolutionize therapeutics and diagnostics industries in healthcare - http://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
MarketsandMarkets

MarketsandMarkets

CELGENE (U.S.), MERCK (U.S.), EISAI (JAPAN), EPIZYME (U.S.), 4SC (GERMANY), NOVARTIS (SWITZERLAND), CELLCENTRIC (U.K.), EPITHERAPEUTICS (DENMARK), CH3 BIOSYSTEMS (U.S.), RIBOMED BIOTECHNOLOGIES (U.S.), COVARIS INC. (U.S.), MERCK MILLIPORE (U.S.)

(PRWEB) July 15, 2014

The report “Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)” analyses the global epigenetics market by region, applications and epigenetic mechanisms with five-year revenue forecasts. It also identifies the factors driving and restraining the global epigenetics market with analysis of trends, opportunities and challenges.

The global market for epigenetics in terms of revenue is estimated to be worth $2.6 billion in 2012 and is expected to reach $8 billion by 2017, growing at a CAGR of 25% from 2012 to 2017.

Get discount on this report @ http://www.marketsandmarkets.com/discountreports.asp?id=896.

The market is segmented and the revenue is forecasted on the basis of major regions such as America, Europe, Asia and Rest of the World (ROW), covering the key countries for each region. Further, the market is also segmented and revenues are forecasted on the basis of applications and disease indications.

In the post genomic era, epigenetics is gaining importance as a promising scientific approach for understanding the influence of the epigenetic mechanisms in cancer and various other diseases. Rapid advancements have been occurring specifically in the field of cancer therapeutics.

The market for epigenetics screening tools such as enzymes, ChIP kits, assays for analyzing various epigenetic mechanisms are increasing at a higher rate due to increased utilization in the research field. There has been a significant growth in biotechnology industry based on the revenues from epigenetic tools. The pharmaceutical industry also experienced a considerable growth based on sales revenues of the four epigenetic drugs, for example, around $1 billion in the year 2011, and it is expected to have an increased growth rate in the coming years.

For More Inquiries: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=896

The Global Epigenetics market is showing a double digit growth (CAGR 25%) due to supportive factors such as (i) huge amount of funds and investments, (ii) increasing partnerships and collaborations, and (iii) rapid screening tools. Epigenetics is used in the identification of new epigenetic biomarkers which will aid in better diagnosis and prognosis of diseases. While there are factors favoring the market growth, there are concerns such as change in reimbursement systems and lack of predictive markers holding back the growth of this market. However, the positive aspects in this field may very well offset the market restraints to aid the market grow at an exceptional rate.

Strong academic research, high demand for treatment of cancer and non-oncology conditions, rapid screening tools are some of the factors driving the epigenetics market. Therapeutic applications in non-oncology indications such as inflammatory diseases, autoimmune diseases, neurodegenerative disorders and personalized medicine are some high growth and emerging areas that are expected to drive the global market of epigenetics in coming years.

The key participants in the global epigenetic market are Celgene (u.s.), Merck (u.s.), Eisai (japan), Epizyme (u.s.), 4sc (germany), Novartis (switzerland), Cellcentric (u.k.), Epitherapeutics (denmark), CH3 biosystems (u.s.), Ribomed biotechnologies (u.s.), Covaris inc. (u.s.), Merck Millipore (u.s.), Epiontis (germany).

Browse Related Reports:
Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018
http://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html

Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013 – 2018)
http://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales(at)marketsandmarkets(dot)com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals.
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets.


Contact